Home health remedies Expert Forum Examines the Patent Content Expansion Plan for Reaxys

Expert Forum Examines the Patent Content Expansion Plan for Reaxys

14
0
SHARE

Posted on May 21st, 2021 by in Chemistry

User feedback is instrumental to the evolution of Reaxys. Not only
in articulating what works and what is missing, but also in guiding the
direction of newly developed capabilities to meet user information needs.

For decades, Reaxys has
offered highly interconnected chemistry knowledge spanning domains critical to
the pharmaceutical industry. The scope and granularity of data in Reaxys
supports informative knowledge visualization and analytics, customized queries,
and an award-winning predictive retrosynthesis tool. Coverage of
chemistry-related patents, however, had been limited to a handful of offices.
The mandate of the Reaxys development team to guarantee data quality meant that
patent content had to be excerpted manually, which necessarily limited
accession volume.

Now, advances in semantic
processing and machine learning resolves that bottleneck. In February, Elsevier
and LexisNexis announced a collaboration to augment Reaxys content with patents
from 105 patent offices and 170 IPC classes. As of January, Reaxys indexes bibliographic
information from those patent offices, and a priority subset of offices and IPC
classes are undergoing biological target enrichment. This content pipeline
makes patent titles, abstracts, authors, claims translated to English and
documented targets discoverable within five days of publication.

Reaxys aims to help pharma users succeed in a crowded, competitive
landscape. By digitizing chemistry knowledge at large scale, Reaxys delivers
pivotal information to anticipate risks and opportunities that can make or
break a drug development program. With the augmented patent content, Reaxys
aims to answer questions like “Which patents address my biological target?”,
“Is this patent active for my target and indication?”, and “Which company owns
this patented innovation?”

Essential to the success of this competitive intelligence workflow is ensuring that it truly meets the data needs and work style of pharma experts, both for the lab and for intellectual property analysis. So, the Reaxys team organized The Expert Forum to introduce the new capabilities in Reaxys, outline the technology and machine learning-powered processing “under the hood” of the content expansion project, and gather feedback to guide its continued evolution.

Lead Product Manager Dr. Rosalind Sankey and Head of Chemistry Solutions Dr. Ivan Krstic joined Directors of Data Science Dr. Saber Akhondi and Umesh Nandal in presenting the inherent challenges of enriching target and compound information in patent documents – from capturing and normalizing the many ways that information is reported to accurately determining the relevance of each identified entity to the claims of a patent. Saber and Umesh also described how innovative natural language processing and machine learning overcome these challenges, achieving a throughput that matches current patent publication rates while keeping true to the high quality standards of Reaxys. Finally, in a 40-minute dialogue, attendees asked and learned about anticipated content growth and the underlying quality assurance mechanisms. They also voiced suggestions for presenting the data in the user interface to maximize usability.

The currently live patent content pipeline is only the beginning.
In a next step, substance enrichment will power novelty searching and answer
the question “What chemical space is protected?” As an evolving endeavor, the
team will continue to seek feedback and insights from users to ensure the
relevance of project outcomes. Additional Expert Forums will take place to
capture a diversity of opinions across Reaxys projects.

If you are interested in joining one of these events, please join the LinkedIn group where we will post updates and more information relating to the next Expert Form.

Please enable JavaScript to view the comments powered by Disqus.

R&D Solutions for Pharma & Life Sciences

We’re happy to discuss your needs and show you how Elsevier’s Solution can help.

Contact Sales

!function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()
{n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
;if(!f._fbq)f._fbq=n;
n.push=n;n.loaded=!0;n.version=’2.0′;n.queue=[];t=b.createElement(e);t.async=!0;
t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
document,’script’,’https://connect.facebook.net/en_US/fbevents.js’);
fbq(‘init’, ‘533182150132648’);
fbq(‘track’, “PageView”);
!function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()
{n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
;if(!f._fbq)f._fbq=n;
n.push=n;n.loaded=!0;n.version=’2.0′;n.queue=[];t=b.createElement(e);t.async=!0;
t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
document,’script’,’https://connect.facebook.net/en_US/fbevents.js’);
fbq(‘init’, ‘1737613393127776’,
{ em: ‘insert_email_variable,’ }
);
fbq(‘track’, ‘PageView’);

Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

5 × four =